



DPP-IV Structural similarities in rat and human

R. J. Vargas*, R. A. Higueros, D. G. Saldaña and L. Y. Xajil

School of Pharmacy, Faculty of Chemical Sciences and Pharmacy, San Carlos de Guatemala University, Campus, Zone 12, Guatemala City

ABSTRACT

The dipeptidyl peptidase-4 DPP-IV is the major receptor of the new oral treatments for diabetes type II. This work determined the structural similarities of the protein DDP-IV of the rat and the human through the global alignment in three dimensions and the aminoacidic sequence. The parameters of structural difference of identity between two proteins 0.751 RMSD and high percent identity 83.56% does not localize in the active site of the enzyme, concluded that activity in both species are similar. The important results are useful in the area preclinical, clinical and developments of drugs that focus in the treatment of diabetes type II.

Keywords: in silico; structural similarities; DDP-IV; Diabetes type II; Rat.

INTRODUCTION

The three-dimensional structure of the DPP-IV from the rat, *Rattus Novergicus* [1] the native human obtained in 2007 [2] shows structurally that both possess a similar domain in its native shape, as is expected to happen when a model organism is used for studies of pharmacological importance. Its similarity is due to an evolutionary conservation in both mammals [3]. There are structural differences in both proteins which, when being away from the potential active site, support the hypothesis that the pharmacophoric domain is similar. The pharmacological effect attributed in a preclinical stage in a rat can be equivalent in a clinical stage in humans.

Currently there are animal models used in the study of type II diabetes, such as the case of Zucker diabetic fatty (ZDF) [4]. Although the ZDF model has two modified genes, there is no evidence that these genes affect the protein conformation of the enzyme DPP-IV [5].

Many drugs have been evaluated in rat on its effect on the enzyme DPP-IV, and sustained human studies [6][7], so that a structural analysis of the similarities in the domain are of relevant importance in the study of the DPP-IV in rat and human.

EXPERIMENTAL SECTION

Through Protein Data Bank obtained the sequences and structures of the 2ONC.PDB for human and the 2GB.PDB of the rat. The sequences alignment performed by the algorithm Needleman-Wunsch [8] as implemented in the Chimera UCSF v1.9. [9]. At a global alignment, the Needleman-Wunsch algorithm used with an assigned BLOSUM-62 value, 30% of the second structure weighting and the remaining weight attributed to the residue similarities.

The gap space assigned by a penalization of 01, 2 Amstrongs as the limit value for the distance among atoms and 5 Amstrongs as a limit for main residue atoms not equally aligned or above the aforementioned value.

The mean root square (RMSD) was used as the deviation criteria at the superposition. The previous value was also obtained by the Chimera UCSF v.1.9 in which, each folding site was analyzed as a deviation; sequence analyses was performed only at the chain B of the corresponding protein. RMSD not analyzed Chain A, as the main goal of the research was to study the prospectus active site, located at chain B.

In both chains of the selected sequences A and B for human and rat performed sequence alignment. Whether the protein structure and function are highly similar, proteins with structure similarities are likely to possess similar functions. The method that pretends to fix two structures according to the RMSD used the 3-dimension alignment at Chimera UCSF Chimera.


RESULTS AND DISCUSSION

Table 1 Structural comparison between 2ONC.PDB and 2GBC.PDB (chain b)

Calculation	value
RMSD	0,751
Sequence lengths	728730
SDM (cutoff 5,0)	14.972
% identity	83,56

Table 1 shows the results of aligning the sequences of rat and human native, likewise, in Figure 2 show the sequence in their primary structure in alignment. The superimposed structures obtained and aligned in three dimensions; Figure 1 shows one of the potential active site amino acid present in both structures.

Figure-1: Histidine 740/741 amino acid present in both superimposed structures



The percentage of identity of chain B of both structures showed considerable disparities at a structure level, close to 17% different among them, however, aminoacids located at the prospectus active site of the DPP-IV S630 and the most important aminoacids located at H740 [10][11] are aligned as showed in Figure 1. Deviation between both structures is negligible (0.886) and aminoacids His740, Ser630 and Tyr547 are placed identically in both proteins.

Aminoacids alignment of both sequences is showed in Figure 2, where the similarity is the highest, however, regardless alignment may be seen in most of them, there're some aminoacidic differences, which explains the difference in the percentage of identity, as well as the 3-dimension deviation. This is possibly because both proteins has been highly conserved at a point the active site has remained closely intact. The RMSD computed in Table 1 has been coupled to changes of the aminoacids located throughout the structure, however as the aforementioned residues are likely to be similar in the prospective active site, their 3-dimension conformation is identical. Thus a ligand would show an identical pharmacodynamics behavior among both in rat as in human in its native structure. similar results were obtained in previous studies made in animal models (e.g. rats) for the evaluation of inhibitors of DPP-IV where the results in animals were considerably different as the obtained in humans [11][12][13].

Thus, inferring the current changes are not due to the differences at the receptor site but due to other enzymes related with the pharmacological metabolism pathway.

Figure-2: Aminoacidic Sequences of chain B of 2ONC.PDB and 2GBC.PDB

	1	11	21	31	41
RMSD					
2onc, chain B	36	HHA S AKTYTL TDYLNKTYRL KLYSLRWISD HEYLYK QEN . . . NIVLNFNAE			
2gbc, chain B	38RRTYTL ADYLNKTRV KSYSLRWVSD SEYLYK. . . Q ENNILLNFNAE			
	51	61	71	81	91
RMSD					
2onc, chain B	83	YGNSSVFLEN STFD EF SH. . . SINDYSISPD GQFILLEYNV VKQWRHSYTA			
2gbc, chain B	81	HGNSSIFLEN STEE. I. FSD SIDSYSVSPD RLFVLLLEYNV VKQWRHSYTA			
	101	111	121	131	141
RMSD					
2onc, chain B	131	SYDIYDLNKR QLITEERIPN NTQWVTWSPV GHKLAYVWNN DIYVKIEE PNL			
2gbc, chain B	129	SYSIYDLNKR QLITEEKIPN NTQWITWSQE GHKLAYVWKN DIYVKIEE PHL			
	151	161	171	181	191
RMSD					
2onc, chain B	181	PSYRITWTGK EDIYNGITD WVYBEEVPSA YSALWNSPNG TFLAYAQFND			
2gbc, chain B	179	PSHRITSTGK ENVIFNGIND WVYBEEIFGA YSALWNSPNG TFLAYAQFND			
	201	211	221	231	241
RMSD					
2onc, chain B	231	TEVPLIEYSF YSDESLSQYFK TVRVFPYKAG AVNPTVKFFV VNTDSL. S SV			
2gbc, chain B	229	TEVPLIEYSF YSDESLSQYFK TVWIPYKAG AVNPTVKFFI VNTDSL. S S . T			
	251	261	271	281	291
RMSD					
2onc, chain B	280	TNATSIQITA PASMLICDHY LCDVFWATQE RISLQWLRRV QNYSVMDCD			
2gbc, chain B	278	TTIIPMQITA PASVTTGDHY LCDVAVVSD RISLQWLRRV QNYSVMAICD			
	301	311	321	331	341
RMSD					
2onc, chain B	330	YDESSGRWNC LVARQHIEM S T T GWVGRFRP SEP H PTLDGN SFYKII S NEE			
2gbc, chain B	328	YDKTTLVWNC PTTQEHIE T S ATGWCGRFRP AEP H PTSDGS SFYKIV S DKD			
	351	361	371	381	391
RMSD					
2onc, chain B	380	G Y RHICYPQI DKK. . . D. CTF ITKGTNEVIG IEALTS D YLY YISNEYK Q ME			
2gbc, chain B	378	G Y KHICQPK DRK P EQVCTF ITKGA N EVIS IEALTS D YLY YISNEYK E ME			
	401	411	421	431	441
RMSD					
2onc, chain B	427	GGRNLYKIQL SDYTKVTCLS CELNPERCOY YSVSFSKEAK YYQLRCSGPG			
2gbc, chain B	428	GGRNLYKIQL TDHTNKKCLS CDL N PERCOY YSV S LKRAK YYQL C GRGPG			
	451	461	471	481	491
RMSD					
2onc, chain B	477	LPLYTLHSSV NDKGLRVLED NSALDKMLQN VQMP S KKLDF IILNETK F WY			
2gbc, chain B	478	LPLYTLHRST DQKELRVLED NSALDKMLQD VQMP S KKLDF IVLNETR F WY			
	501	511	521	531	541
RMSD					
2onc, chain B	527	QMILPPHFDK SKKYPLLDV YAGPCSQKAD TVFRLNWATY LASTENIIVA			
2gbc, chain B	528	QMILPPHFDK SKKYPLLDV YAGPCSQKAD AAFRLNWATY LASTENIIVA			
	551	561	571	581	591
RMSD					
2onc, chain B	577	SFDGRGSGYQ GDKIMHAINR RLGT F EVEDQ IEAARQ F SKM GFVDN K RIAI			
2gbc, chain B	578	SFDGRGSGYQ GDKIMHAINK RLGT F EVEDQ IEAARQ F LKM GFVD S KRVAI			
	601	611	621	631	641
RMSD					
2onc, chain B	627	WGWSYGGYVT SMVLGSGSGV FKCGIAVAPV SRWEY Y DSVY TERYMGL P TF			
2gbc, chain B	628	WGWSYGGYVT SMVLGSGSGV FKCGIAVAPV SRWEY Y DSVY TERYMGL P TF			
	651	661	671	681	691
RMSD					
2onc, chain B	677	EDNLDHYRNS TVMSRAENFK QVEYLLIHGT ADDNVHFQQS AQISKALVDV			
2gbc, chain B	678	EDNLDHYRNS TVMSRAENFK QVEYLLIHGT ADDNVHFQQS AQISKALVDA			
	701	711	721	731	
RMSD					
2onc, chain B	727	GVDFQAMWYT DEDHG I ASST AHQHIYTHMS HF I KQCFSL E			
2gbc, chain B	728	GVDFQAMWYT DEDHG I ASST AHQHIYSHMS HF L QQCFSL R			

CONCLUSION

The results of the compared 3D structure, Rattus Novergicus 2GBC.PDB and human Native structure 2ONC.PDB, show that both enzymes are identical in the potential active site and the differences are located in the aminoacids on peripheral sites. For this reason the mutations do not modified the response of active site facing a ligand, and the activities of both species must be identical.

Acknowledgment

This study was possible through co-financing, given the number 20-2013 Fodecyt project, funded by the National Secretariat of Science and Technology SENACYT. The authors express their gratitude to all staff of the pharmacogenetics laboratory at Universidad de San Carlos de Guatemala and J.F. Carrascoza Mayen from Chemistry Department of Babes-Bolyai University, Romania, for reviewing the final document.

REFERENCES

- [1] K L Longenecker: KD Stewart: DJ Madar: CG Jakob: EH Fry S. *Biochemistry*, **2006**, 45(24), 7474-7482.
- [2] J Feng: Z Zhang: MB Wallace: JA Stafford: SW Kaldor: DB Kassel: SL Gwaltney *Journal of medicinal chemistry*, **2007**, 50(10), 2297-2300.
- [3] J Wiesner: Z Kríz: K Kuca: D Jun: J Koca. *Journal of enzyme inhibition and medicinal chemistry*, **2007**, 22(4), 417-424.
- [4] M Beppu: R Hoshikawa: K Sudo: A Kawada: S Takagi: S Seino. *Experimental Diabetes Research* **2013**, 1-9
- [5] JB Clark: CJ Palmer: WN Shaw. *Experimental Biology and Medicine*, **1983**, 173(1), 68-75.
- [6] T Karagiannis: P Boura: A Tsapas. *Therapeutic Advances in Drug Safety*, **2014**, 5(3), 138-146.
- [7] T Yoshida: F Akahoshi: H Sakashita: H Kitajima: M Nakamura: S Sonda: Y Hayashi. *Bioorganic & medicinal chemistry*, **2012**, 20(19), 5705-5719.
- [8] SB Needleman: CD Wunsch. *Journal of molecular biology*, **1970**, 48(3), 443-453.
- [9] EF Pettersen: TD Goddard: CC Huang: GS Couch: DM Greenblatt: EC Meng: TE Ferrin. *Journal of computational chemistry*, **2004**, 25(13), 1605-1612.
- [10] K Aertgeerts: S Ye: MG Tennant: ML Kraus: J Rogers: BC Sang: GS Prasad. *Protein science*, **2004**, 13(2), 412-421.
- [11] BD Patel: MD Ghate. *European journal of medicinal chemistry*, **2014**, 74, 574-605.
- [12] JA Davis: PS Kumar: S Singh: A Surender: S Roy: V Khanna: VS Bansal. *Indian journal of pharmacology*, **2012**, 44(6), 759.
- [13] RA Pederson: HA White: D Schlenzig: RP Pauly CH McIntosh: HU Demuth. *Diabetes*, **1998**, 47(8), 1253-1258.